Saturday, 20 December 2014

The 10 Largest Pharmaceutical Companies In the World

Hi all,
            Came across a lit of 10 largest pharmaceutical companies in the world. Worth noting.

The collective biotech and pharmaceutical industry is known to be one of the most active and wealthy industries in the world, considering the global pharmaceutical market is worth about $1 trillion. Furthermore, within modern societies, the increased usage of medicines and medications for treating almost every illness (or perceived illness) is likely to keep raising demand for these products, and thus continue bursting pharmaceutical companies’ sales and revenue.

SN
Company
Country
Revenue
1
Johnson & Johnson
USA
USD 71.3 Billion
2
Novartis
Switzerland
USD 60.9 Billion
3
Roche
Switzerland
USD 52.4 Billion
4
Pfizer
USA
USD 51.6 Billion
5
Sanofi
France
USD 45.8 Billion
6
Merck
USA
USD 44.0 Billion
7
GlaxoSmithKline
UK
USD 43.9 Billion
8
AstraZeneca
UK
USD 27.2 Billion
9
Elli Lilly
USA
USD 23.1 Billion
10
Abbott Laboratories
USA
USD 21.8 Billion


Happy reading.


Friday, 19 December 2014

QIP_Frontiers in Pharmacology of Drug research & Recent trends in pharmacy practice


AICTE Sponsored Quality Improvement Programme is being organized by Manipal College of Pharmaceutical Sciences, Manipal University, Manipal – 576104, Karnataka. The two-week programme is designed to provide a fine mix of lectures and demonstrations. Resources persons from host departments and other institutions with expertise in their fields will deliver lectures meant to give an insight into innovative drug development. There have been several advances in drug development in the recent past. This programme will familiarize the participants with these and the emerging trends in drug development. There would be demonstrations of experiments with sophisticated instruments involving cell culture techniques, Elisa and Flow cytometer etc.
 
The details are as follows:
Theme: Frontiers in Pharmacology of Drug research & Recent  trends in Pharmacy Practice.
 
Dates: 5th to 17th January 2015.
 
Organized by: Manipal College of Pharmaceutical Sciences, Manipal University, Manipal – 576104, Karnataka.
 
Location: Manipal.
 

Thomson Reuters’ India Innovation Awards 2014 for Sun pharma and Biocon

Biocon and Sun Pharma were honoured at Thomson Reuters’ India Innovation Awards 2014, announced at the recent launch of its 2014 State of Innovation India report. This is the second consecutive year of the study, which analyses innovation in 12 leading sectors based on patent activity for inventions originating from India, using the Derwent World Patents Index, Thomson Reuters’ proprietary patent database.
Hi-tech engineering and pharma companies emerged as front runners of innovation in India. The study showcases twelve leading sectors and analyses the innovation in each based on patent activity.
“India is an important global innovation hub, with both local and global organizations conducting critical R&D activities in India. Patenting activity is growing rapidly and this has a direct impact on the country’s economic growth,” said Pradeep Lankapalli, Managing Director, India and head of global operation centres, Thomson Reuters India.
The India Innovation Awards are designed to recognise innovation and entrepreneurship in India, based on Indian patent publications. The awards honour the most innovative academic institutions and commercial enterprises headquartered in India for their spirit of innovation in R&D
 
Reacting to the award Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon commented, “Our focus on innovation has enabled Biocon to cross new milestones in the area of drug affordability through our range of biosimilars and biologics. The Thomson Reuters India Innovation Award 2014 validates the work that Biocon is doing in our pursuit to find solutions that heal the world.”
Dr Rajamannar Thennati, Head – R&D, Sun Pharma, said, ”At Sun Pharma, innovation is the core of our organisation. In our business, innovation is directly linked to helping patients by providing medicines at affordable cost. We are focussed on finding solutions to complex scientific challenges, environmental safety and creating an intellectual asset for sustained growth.”
 

Monday, 15 December 2014

Two Days National Conference on Drug Discovery and Drug Targeting in Metabolic Diseases

Shri Vile Parle Kelavani Mandal’s Dr. Bhanuben Nanavati College of Pharmacy is organizing “Two Days National Conference on Drug Discovery and Drug Targeting in Metabolic Diseases” in Mumbai.
 
There is a powerful interplay of nutrition and metabolic alterations that lead to metabolic disorders. A large proportion of metabolic disorders go largely undetected due to lack of awareness. Metabolic disorders have a disproportionately high prevalence in the Indian population. Cardiovascular diseases, diabetes, obesity and dyslipidemia, though traditionally treated as separate entities, are often conditions that appear together in individuals because of defects in underlying metabolic processes.

 
The sessions are aimed to discuss the impact of this paradigm change in the way drugs are discovered, developed and targeted in the metabolic diseases arena and to stay abreast of the latest targets and drug development candidates in the pipeline.
 
The details are as follows:
Theme:             "Two Days National Conference on Drug Discovery and Drug Targeting in Metabolic Diseases".

Dates:              December 22, 23, 2014.

Sponsor:          DBT and ICMR.

Location:         Juhu Jagruti Auditorium & Seminar Hall, SVKM Campus, V.M. Road, Vile Parle (W), Mumbai – 400 056, Maharashtra.

Details:            http://bncp.ac.in/Common/Uploads/HomeTemplate/CDoc_BNCP%20Conference%20Flyer.pdf
 



 

 

Wednesday, 10 December 2014

Journal Impact factors

Hi All,
We publish so many articles in so many journals. Usually number of publications is considered as the criteria about the research experience in academics. However, what plays more role is the quality of journal which is determined by Impact factor.
 
You must have heard about Impact Factor of a journal. What it is?
 
Wikipedia defines "The impact factor (IF)" of an academic journal is a measure reflecting the average number of citations to recent articles published in that journal. It is frequently used as a proxy for the relative importance of a journal within its field, with journals with higher impact factors deemed to be more important than those with lower ones. The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information. Impact factors are calculated yearly starting from 1975 for those journals that are indexed in the Journal Citation Reports.
 
The Impact factor of any journal is available online and can be accessed at:
 
So, next time before sending an article for publication, check out the impact factor of the journal.
 
 

Tuesday, 9 December 2014

QbD in Pharma Development World Congress 2015

The 3rd Annual International conference “QbD in Pharma Development World Congress 2015” is being organized this year in Chandigarh. The event will feature experts who are adept in this science and risk-based approaches, and therefore, will offer definitive benefits to the scientists from academia and industry working in the domains of Product Development, Process R & D, Scale-up, Manufacturing, Quality Assurance, Global Regulatory Affairs, API, Excipients, Pharmaceutical Analysis and Technology Transfer. The speakers will articulate on all the pertinent areas of QbD Implementation including Manufacturing, Formulation, Analytical Development and Excipients.

The details are as follows:
Theme:             "Emerging Challenges, Federal Issues & Possible Solutions".

Dates:               April 16-18, 2015.

Location:           Hotel Shivalik View, Chandigarh, India.

First batch of Pharm.D pass-outs gets lucrative placements

Pharmabiz reports that most of the well-known Pharm.D institutes and colleges in the country have successfully provided placements to the first batch of Pharm.D pass-outs, with some of them gearing up to find lucrative jobs in the market, thanks to the focus on patient-oriented rather than product-oriented Pharm.D course.
 
“Several aspirants have chosen to travel overseas for their careers hoping to find careers in community and hospital settings. Since there is a great demand for starting of Pharm.D programme in the institutions, they are also finding careers in academic settings,” Dr B Suresh, vice chancellor, JSS University, Mysore & president, Pharmacy Council of India, New Delhi, confirms to Pharmabiz.
 
 
 
 

7th International Symposium on Drug Metabolism & PharmacoKinetics

7th International Symposium on Drug Metabolism & PharmacoKinetics is being organized in NIPER, Mohali.
 
This is primarily a lecture-based symposium intended for students and scientists from industry, academia, 
health-based government organizations, and healthcare professionals with a background in chemistry, biology, and the pharmaceutical sciences, with some experience in the principles and techniques of drug metabolism and pharmacokinetics.  The symposium is also intended for experienced researchers in these areas who wish to broaden or supplement their area of expertise, as well as contribute to the discussion topics.

The details are as follows:
Theme:            7th International Symposium on Drug Metabolism & PharmacoKinetics.

Dates:               February 18-21, 2015.

Organized by:   NIPER.

Location:           Mohali, Punjab.

Applied Pharmaceutical Analysis-India

The Boston Society® is an internationally-recognized non-profit organization and is dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. It is organizing “Applied Pharmaceutical Analysis-India” in Mumbai.

 
The details are as follows:
Theme:             Increasing Size, Complexity and Potency: The Bioanalytical Challenges of the Next Decade.

Dates:               February 22-25, 2015.

Organized by:   The Boston Society®

Location:           Mumbai.

National Conference on “ Drug Carriers in Medicine and Biology

Department of Biotechnology, Bannari Amman Institute of Technology, Sathyamangalam is organizing a National Conference on “Drug Carriers in Medicine and Biology” during 7-8 January 2015, supported by Science and Engineering Research Board/ Department of Science and Technology and Department of Biotechnology/Ministry of Science and Technology, Government of India, New Delhi.

The details are as follows:
Theme:            National Conference on “Drug Carriers in Medicine and Biology”. Dates:              January 7-8, 2015.

Organized by:  Department of Biotechnology, Bannari Amman Institute of Technology, Sathyamangalam.

Location:          Sathyamangalam - 638 401, Erode District, Tamilnadu, India. Details available at: http://www.bitsathy.ac.in/dcmb2015.pdf
 
 

Competition comission clears Sun-Ranbaxy deal but tells it to sell off 7 brands

Firstpost reports that the drug-makers Sun Pharma and Ranbaxy got fair trade watchdog CCI's {Competition commission of India} approval on Monday for their long-pending USD 4-billion merger, but with a condition that they will have to modify the deal by divesting seven key products to address monopoly concerns.

This move would create the country's largest pharmaceutical company post the merger between Sun Pharma and Ranbaxy Laboratories.
Under the conditions, Sun Pharma will divest products involving Lueprorelin. The divest products will include Tamplet and Lupride.

On the other hand, Ranbaxy Laboratories will divest products such as Raciper L, Terlibax, Triolvance, Olanex F and Rosuvas EZ.

Source:
http://firstbiz.firstpost.com/corporate/cci-clears-sun-ranbaxy-deal-but-tells-it-to-sell-off-7-brands-112308.html

http://zeenews.india.com/business/news/companies/cci-approves-sun-pharma-ranbaxy-deal-creates-india-s-largest-pharma-co_113679.html
 

Friday, 5 December 2014

PHARMACY COUNCIL OF INDIA - NOTIFICATION

The recent government notification published details about the
"Minimum requirements of academic qualifications, teaching, research and industry experience for teaching posts in pharmacy colleges/institutions".
 
Diploma course:

Name of Post

Academic qualification

Teaching/Research/Industry experience

Principal/Director/

Head of institute/

Head of department

PCI recognized Post Graduate qualification in any discipline of pharmaceutical sciences.

OR

PCI recognized Pharm. D.

Essential:

5 years teaching experience in PCI approved/recognized Pharmacy College.

Desirable:

Administrative experience in a responsible position.

Lecturer

(Pharmacy subjects)

PCI recognized M.Pharm/ Pharm. D.

OR

PCI recognized B. Pharm

(i) A person holding M.B.B.S. qualification can be considered for the post of Lecturer in the subjects of Anatomy & Physiology and Bio- Chemistry & Clinical Pathology.

(ii) A person holding M.Sc. (Maths) degree shall be eligible for the post of Lecturer (Mathematics) on part-time basis.

(iii) A person holding M.Sc. (Zoology) or M.Sc. (Botany) degree shall be eligible for the post of Lecturer (Biology) on part-time basis.

(iv) A person holding B.E. (C.S.) or MCA degree shall be eligible for the post of Lecturer (Computer Science) on part-time basis.

 

B. Pharm / Pharm.D. /Post graduate course in Pharmacy:
Name of Post
Academic qualification
Teaching/Research/Industry experience
Director/Principal/
Head of Institution
First Class B. Pharm with Master’s degree in Pharmacy (M.Pharm) in appropriate branch of specialization
in Pharmacy or Pharm.D (Qualifications must be PCI recognized). With Ph.D degree in any of Pharmacy subjects (Ph.D. Qualifications must be PCI recognized).
Essential:
15 years experience in teaching or research out of which 5 years must be as
Professor/HOD in a PCI approved/ recognized pharmacy college.
 
Desirable:
Administrative experience in a responsible position.
Professor
First Class B.Pharm with Master’s degree in Pharmacy (M.Pharm) in appropriate branch of specialization in Pharmacy or Pharm. D (Qualifications must be PCI recognized).
With Ph.D degree in any of Pharmacy subjects (Ph.D. Qualifications must be PCI recognized).
Essential:
10 years experience in teaching in PCI approved/ recognized Pharmacy College or research experience out of which 5 years must be as Associate Professor in PCI approved/recognized Pharmacy College.
Associate Professor
First Class B.Pharm with Master’s degree in Pharmacy (M.Pharm) in appropriate branch of specialization in Pharmacy (Qualification must be PCI recognized).
 
A PCI recognized Pharm.D degree holder shall also be eligible for the posts of Associate Professor in the
subjects of pathophysiology, pharmacology sand pharmacy practice.
 
Associate Professor shall acquire PCI recognized Ph.D in any of Pharmacy subjects within 7 years to become eligible for the post of Professor.
3 years experience in teaching or research at the level of Assistant Professor or equivalent in PCI approved/ recognized Pharmacy College.
 
Lecturer/Assistant Professor
First Class B.Pharm with Master’s degree in Pharmacy (M.Pharm) in appropriate branch of specialization in Pharmacy (Qualification must be PCI recognized).
A PCI recognized Pharm.D degree holder shall also be eligible for the posts of Lecturer/Assistant Professor in the subjects of pathophysiology, pharmacology and pharmacy practice.
A lecturer will be re-designated as Assistant Professor after 2 years of teaching experience in PCI approved/ recognized Pharmacy College.
 
The details of the notification are available at:
http://www.pci.nic.in/Circulars/Teachers%20Education%20Regulation.pdf

 

Thursday, 4 December 2014

12th National Pharmaceutical Conclave

CII and DIPP are organizing "12th National Pharmaceutical Conclave" in New Delhi.

The conclave intends to focus on the issues that need urgent attention of the industry stakeholders. Further, it endeavours to bring the decision makers together so that the discussions result in meaningful actionable outcomes.

The details are as follows:

Theme:                         Make, Develop and Innovate in India.

Dates:                          12th and 13th December 2014.

Organized by:               CII and DIPP, Government of India. 

Location:                      New Delhi.

Details available at:         http://www.nationalpharmaconclave.com/index.php


 
 
 
 

Tuesday, 2 December 2014

Department of Pharmaceuticals pondering over price monitoring cells

The Department of Pharmaceuticals is considering setting up price monitoring cells in all states to provide technical assistance to drug controllers and the National Pharmaceutical Pricing Authority (NPPA). The price monitoring cells will render technical assistance to State Drug Controllers and NPPA in monitoring the notified price of medicines, price movement of scheduled/non-scheduled formulations, collection/monitoring availability of drugs as required under provisions of DPCO.